Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -183.0%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $3M | $3M | $6M | — | — | — |
| Enterprise Value | $-614587 | $917395 | $-2137842 | $3M | — | — | — |
| P/E Ratio → | -0.20 | — | — | — | — | — | — |
| P/S Ratio | 13.45 | 26.58 | — | 88.89 | — | — | — |
| P/B Ratio | 0.60 | 1.45 | 0.66 | 2.23 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.86 | — | 48.51 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 17.3% | 17.3% | — | 92.0% | 92.0% | — | — |
| Operating Margin | -5652.4% | -5652.4% | — | -8257.7% | -24558.0% | — | — |
| Net Profit Margin | -5569.6% | -5569.6% | — | -8239.8% | -28024.9% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -183.0% | -183.0% | -185.1% | -206.6% | — | — | — |
| ROA | -155.5% | -155.5% | -167.9% | -374.9% | -6201.4% | -7794.1% | -6807.9% |
| ROIC | — | — | — | — | — | — | — |
| ROCE | -185.8% | -185.8% | -191.5% | -207.1% | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.02 | -1.10 | -1.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -1153.39 | -1153.39 | -384.16 | -66.72 | -7.07 | -13.50 | -28.04 |
Net cash position: cash ($2M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.85 | 3.85 | 9.43 | 15.03 | 0.02 | 0.01 | 0.01 |
| Quick Ratio | 3.85 | 3.85 | 9.43 | 15.03 | 0.02 | 0.01 | 0.01 |
| Cash Ratio | 3.25 | 3.25 | 9.24 | 14.24 | 0.02 | 0.01 | 0.01 |
| Asset Turnover | — | 0.04 | — | 0.02 | 0.12 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $10M | $8M | $6M | $6M | $6M | $6M |
Liquidity and insolvency risk
According to recent financial filings, the company trades at a price-to-sales ratio of 13.45, a multiple that appears disconnected from its negligible TTM revenue of $116,670 and suggests that market participants are pricing in extreme binary outcomes rather than fundamental operational performance or near-term cash generation.
The current valuation reflects a high-risk lottery ticket profile where investors are betting on the potential success of the bfLEAP platform rather than current earnings. Given the lack of positive net income or EBITDA, traditional valuation metrics are largely irrelevant, and the current P/S ratio likely overstates the company's intrinsic value relative to its peers.
As reported in quarterly financial statements, the company's operating margin of -5652% highlights a severe disconnect between its high fixed-cost structure and its current commercial output, indicating that the business is currently in a pre-revenue or early-pilot phase rather than a scalable commercial stage.
The gross margin of 17.29% is notably thin for a technology-focused firm, suggesting that the costs associated with data acquisition and cloud computing are currently consuming a significant portion of the company's limited revenue. This margin profile warrants further investigation into whether the company can achieve operating leverage as it scales its licensing model.
Based on the latest quarterly data, the company's cash position has dwindled to approximately $2.18 million, a figure that appears insufficient to sustain its current burn rate for more than a few quarters without additional capital infusion or a major commercial milestone.
While the current ratio of 8.15 suggests a strong short-term liquidity position on paper, this is largely an artifact of the company's low current liabilities rather than an abundance of cash. Investors should monitor the company's ability to secure non-dilutive funding, as the current cash runway is a critical constraint on its ability to advance its therapeutic pipeline.
As indicated by the company's financial structure, the use of P/S or EV/EBITDA multiples is fundamentally misapplied to this business model, as it obscures the binary clinical risk and the reality that the firm functions more like a virtual biotech than a scalable software-as-a-service provider.
Analysts should instead focus on 'burn-adjusted' valuation models or the probability-weighted net present value of the company's licensed therapeutic assets. Relying on standard software multiples ignores the reality that the company's survival is tied to clinical trial outcomes rather than the recurring revenue growth typically associated with the information services sector.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BFRGW stock.
Bullfrog AI Holdings, Inc. Warrants's current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Bullfrog AI Holdings, Inc. Warrants's return on equity (ROE) is -183.0%. The historical average is -191.6%.
Based on historical data, Bullfrog AI Holdings, Inc. Warrants is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bullfrog AI Holdings, Inc. Warrants has 17.3% gross margin and -5652.4% operating margin.